Chester County News and Community Website
EXTON, PA — Castle Creek Biosciences, Inc. announced that the U.S. Food & Drug Administration (FDA) Office of Orphan Products Development (OOPD) recently awarded the company a $1.825 million research …
Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this weekannounced results from the Phase 3 ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced the recent approval of Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune disorder. Rethymic is …
Read More
PLYMOUTH MEETING, PA — ECRI announced a new partnership with the U.S. Food and Drug Administration (FDA) to improve the safety of medical devices through the use of safer materials. …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration authorized marketing of software this week to assist medical professionals who examine body tissues (pathologists) in the detection of areas that …
Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that this week the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the publication this week of results from the Company’s open-label Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy …
Read More
WILMINGTON, DE — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced …
Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently granted its request for …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe …
Read More